AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.
AbbVie is making its largest post-Allergan acquisition in a $10.9 billion move for immunology biotech Apogee Therapeutics.
Apogee’s long-acting IL-13 drug, called zumilokibart, is slated …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - AbbVie (NYSE:ABBV), Apogee Ther
AbbVie to buy Apogee Therapeutics in nearly $11B deal
AbbVie Goes On The Offensive With $10.9 Billion Takeover
AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News
Pharma: AbbVie schluckt Biotechfirma Apogee für 10,9 Milliarden Dollar
Pharmaindustrie: AbbVie wohl vor Übernahme von Biotechfirma Apogee Therapeutics
AbbVie ultima la compra de la 'biotech' Apogee por 9.500 millones
M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics
AbbVie compra la 'biotech' Apogee por 10.900 millones de d�lares
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent…
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run…
The deal bolsters AbbVie's immunology and inflammation pipeline, answering a key investor question about what comes after Skyrizi.
<p>AbbVie ha raggiunto un accordo per l'acquisizione di Apogee Therapeutics per circa 10,9 miliardi di dollari in contanti,…
AbbVie stärkt mit der Übernahme von Apogee Therapeutics sein Immunologie-Portfolio und setzt auf neue Wachstumstreiber.
